On July 18, 2026, a new publication concerning macimorelin, an oral ghrelin receptor agonist, appeared in the journal Lancet (London, England).
The paper, titled "Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study," describes a phase 1b/2a clinical trial.
The study is identified as randomised, double-blind, and placebo-controlled in design, according to the published title. It addresses safety, pharmacokinetics, and exploratory efficacy endpoints in a heart failure with reduced ejection fraction population, as stated in the publication title.
No specific results, safety findings, or efficacy outcomes were provided in the event data available for this brief. This report reflects only the publication of the study and its stated design and scope, not any conclusions drawn from it.
Readers seeking additional detail should consult the full text through the listed source. For general background on this compound, see the linked compound overview.